Bought ASX.
PAB @ $
0.115 on Wed 2010-04-28
Reasons:- High volatility stock.
- Price travelling in the low range for this stock
- Reducing cash reserves
- No profit
- Large potential in it's possible patent and R&D
Patrys Limited (PAB) is focused on the development of natural human antibody-based therapies for the treatment of cancer. The company is also exploring opportunities to deploy its technologies in additional indications, either internally or through third parties, including cardiovascular, autoimmune and central nervous system disorders.
